Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 92% Improvement Relative Risk Hospitalization time 25% Chest CT score 68% Recovery, dyspnea/oxy.. 67% Recovery, fever 80% Recovery, cough 86% Recovery, headache 80% Recovery, fatigue 75% Recovery, myalgia 75% Recovery, diarrhea 67% Recovery, inappetence 50% Recovery, nausea 67% c19early.org/t Sadeghizadeh et al. IRCT20170128032241N3 Curcumin RCT LATE Is late treatment with curcumin beneficial for COVID-19? Double-blind RCT 42 patients in Iran Lower progression (p=0.021) and shorter hospitalization (p=0.0069) Sadeghizadeh et al., Phytotherapy Research, doi:10.1002/ptr.7844 Favors curcumin Favors control

Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID ‐19 patients: A randomized, double‐blinded, placebo‐controlled trial

Sadeghizadeh et al., Phytotherapy Research, doi:10.1002/ptr.7844, IRCT20170128032241N3
Sadeghizadeh et al., Promising clinical outcomes of nano‐curcumin treatment as an adjunct therapy in hospitalized COVID.., Phytotherapy Research, doi:10.1002/ptr.7844, IRCT20170128032241N3
Apr 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 42 hospitalized moderate/severe COVID-19 patients in Iran, showing lower progression and improved recovery with nano-curcumin. Nano-curcumin 70mg bid for 14 days.
This is the 19th COVID-19 RCT for curcumin, which collectively show efficacy with p=0.0000049.
This is the 24th COVID-19 controlled study for curcumin, which collectively show efficacy with p=0.000000053 (1 in 19 million).
risk of progression, 92.3% lower, RR 0.08, p = 0.02, treatment 0 of 21 (0.0%), control 6 of 21 (28.6%), NNT 3.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 24.5% lower, relative time 0.75, p = 0.007, treatment mean 7.7 (±2.3) n=21, control mean 10.2 (±3.3) n=21.
relative chest CT score, 67.5% better, RR 0.33, p < 0.001, treatment mean 1.3 (±0.82) n=21, control mean 4.0 (±1.8) n=21, day 14.
risk of no recovery, 66.7% lower, RR 0.33, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 21 (14.3%), NNT 10, day 14, dyspnea/oxygen need.
risk of no recovery, 80.0% lower, RR 0.20, p = 0.18, treatment 1 of 21 (4.8%), control 5 of 21 (23.8%), NNT 5.2, day 14, fever.
risk of no recovery, 85.7% lower, RR 0.14, p = 0.04, treatment 1 of 21 (4.8%), control 7 of 21 (33.3%), NNT 3.5, day 14, cough.
risk of no recovery, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 21 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, headache.
risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, fatigue.
risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, myalgia.
risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, diarrhea.
risk of no recovery, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 21 (4.8%), control 2 of 21 (9.5%), NNT 21, day 14, inappetence.
risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, nausea.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sadeghizadeh et al., 29 Apr 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors, trial IRCT20170128032241N3.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit